The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure
Open accessAbstract
OBJECTIVES We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg). BACKGROUND Clinicians have questioned whether patients need to reach the target beta-blocker dose to receive benefit. METHODS; Outcome (Cox-adjusted) was compared with all placebo patients with dose available at the three-month visit (n = 1,845). RESULTS Data indicated somewhat higher risk in the low-dose group compared with the high-dose group. Heart rate was reduced to a similar degree in the two dose groups, indicating higher sensitivity for beta-blockade in the low-dose group. The reduction in total mortality with metoprolol CR/XL compared with placebo was similar: 38% (95% confidence interval [CI], 16 to 55) in high-dose group (p = 0.0022) and also 38% (95% CI, 11 to 57) in the low-dose group (p = 0.010). CONCLUSIONS Risk reduction was similar in the high- and low-dose subgroups, which, at least partly, may be the result of similar beta-blockade as judged from the HR response. The results support the idea of an individualized dose-titration regimen, which is guided by patient tolerability and the HR response. Further research is needed to shed light on why some patients respond with a marked HR reduction and reduced mortality risk on a relatively small dose of a beta-blocker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts
Bristow, M. R., Ginsburg, R., Minobe, W., Cubicciotti, R. S., Sageman, W. S., Lurie, K., Billingham, M. E., Harrison, D. C., & Stinson, E. B. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207223070401 · Cited by 2,270
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationBristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2807 · Cited by 1,303
Waagstein, F., Caidahl, K., Wallentin, I., Bergh, C. H., & Hjalmarson, A. (1989) · Circulation · doi:10.1161/01.cir.80.3.551 · Cited by 446
Self-citationLenarda, A. D. (2000) · PubMed · Cited by 136
Gottlieb, S. S., Fisher, M. L., KJEKSHUS, J. K., DEEDWANIA, P. C., Gullestad, L. L., Vítovec, J., & Wikstrand, J. (2002) · Circulation · doi:10.1161/hc1002.105180 · Cited by 91
Self-citation
Cited by
Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W. J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13800-7 · Cited by 1,872
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00006 · Cited by 479
Willenheimer, R., van Veldhuisen, D. J., Silke, B., Erdmann, E., Follath, F., Krum, H., Ponikowski, P., Skene, A., van de Ven, L., Verkenne, P., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.582320 · Cited by 343
Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials
Felker, G. M., Hasselblad, V., Hernandez, A. F., & O'Connor, C. M. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.018 · Cited by 334
Chatterjee, S., Biondi-Zoccai, G., Abbate, A., D'Ascenzo, F., Castagno, D., Van Tassell, B., Mukherjee, D., & Lichstein, E. (2013) · BMJ · doi:10.1136/bmj.f55 · Cited by 279
Metadata
- Authors
- Wikstrand, J., Hjalmarson, Å. K., Waagstein, F., Fagerberg, B. J., Goldstein, S., Kjekshus, J., & Wedel, H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 40
- Issue
- 3
- Pages
- 491-498
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W40175792
- Cited by
- 283
- References
- 10
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. https://app.cochat.ai/papers/10.1016/s0735-1097(02)01970-8
- The paper
- Wikstrand, J., Hjalmarson, Å. K., Waagstein, F., Fagerberg, B. J., Goldstein, S., Kjekshus, J., & Wedel, H. (2002). Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(02)01970-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.